These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1716603)

  • 1. Pharmacokinetics, effect on clotting tests and assessment of the immunogenic potential of hirudin after a single subcutaneous or intravenous bolus administration in man.
    Bichler J; Siebeck M; Fichtl B; Fritz H
    Haemostasis; 1991; 21 Suppl 1():137-41. PubMed ID: 1716603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of hirudin in man after single subcutaneous and intravenous bolus administration.
    Bichler J; Fichtl B; Siebeck M; Fritz H
    Arzneimittelforschung; 1988 May; 38(5):704-10. PubMed ID: 3415713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of recombinant hirudin.
    Markwardt F; Nowak G; Stürzebecher J
    Haemostasis; 1991; 21 Suppl 1():133-6. PubMed ID: 1894188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
    Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
    J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
    Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
    Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinico-pharmacological studies with recombinant hirudin.
    Markwardt F; Nowak G; Stürzebecher J; Vogel G
    Thromb Res; 1988 Dec; 52(5):393-400. PubMed ID: 3222782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of recombinant hirudin in healthy horses.
    Feige K; Dennler M; Kästner SB; Wunderli-Allenspach H; Demuth D; Huber A
    Equine Vet J; 2004 Mar; 36(2):135-41. PubMed ID: 15038436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time.
    Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
    Haemostasis; 1996; 26(3):140-9. PubMed ID: 8738588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and anticoagulant effect of hirudin in man.
    Markwardt F; Nowak G; Stürzebecher J; Griessbach U; Walsmann P; Vogel G
    Thromb Haemost; 1984 Oct; 52(2):160-3. PubMed ID: 6523433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits.
    Kouz J; Czech J; Nicolay U; Dickneite G
    Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacology of recombinant hirudin, a new anticoagulant.
    Meyer BH; Luus HG; Müller FO; Badenhorst PN; Röthig HJ
    S Afr Med J; 1990 Sep; 78(5):268-70. PubMed ID: 2392724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration.
    Cardot JM; Lefèvre GY; Godbillon JA
    J Pharmacokinet Biopharm; 1994 Apr; 22(2):147-56. PubMed ID: 7815310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the pharmacokinetics and pharmacodynamics of recombinant hirudin (rHV2-Lys 47) after intravenous and subcutaneous administration in dogs.
    Iyer L; Koza M; Iqbal O; Calabria R; Fareed J
    Thromb Res; 1993 Feb; 69(3):259-69. PubMed ID: 8475476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunoassay for the detection of active-site specific thrombin inhibitors in biological fluids. I. Assay characteristics and quantitation of recombinant hirudin.
    Lackmann M; Hoad R; Kakakios A; Geczy CL
    Thromb Res; 1991 Sep; 63(6):595-607. PubMed ID: 1780804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma.
    Boström SL; Hansson GF; Sarich TC; Wolzt M
    Thromb Res; 2004; 113(1):85-91. PubMed ID: 15081569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory assays for the evaluation of recombinant hirudin.
    Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
    Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays.
    Wakui M; Fujimori Y; Nakamura S; Kondo Y; Kuroda Y; Oka S; Nakagawa T; Katagiri H; Murata M
    J Clin Pathol; 2019 Dec; 72(12):817-824. PubMed ID: 31366633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RGD-hirudin-based low molecular weight peptide prevents blood coagulation via subcutaneous injection.
    Li YR; Huang YN; Zhao B; Wu MF; Li TY; Zhang YL; Chen D; Yu M; Mo W
    Acta Pharmacol Sin; 2020 Jun; 41(6):753-762. PubMed ID: 31949293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A recombinant hirudin (IK-HIR02) in healthy volunteers. II. Effects on platelet adhesion and platelet-induced thrombin generation time.
    Schenk JF; Glusa E; Radziwon P; Butti A; Markwardt F; Breddin HK
    Haemostasis; 1996; 26(4):187-94. PubMed ID: 8872129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the pharmacokinetics of hirudin.
    Markwardt F; Nowak G; Stürzebecher U; Walsmann P
    Biomed Biochim Acta; 1987; 46(4):237-44. PubMed ID: 3632647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.